Non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain may be treated with EGFR–tyrosine kinase inhibitors (TKIs), including erlotinib and gefitinib. Here, EGFR is linked to non-small cell lung carcinoma.